The U.S. Food and Drug Administration has granted fast track designation for the CPI-613 (devimistat; Rafael Pharmaceuticals, Inc), for the treatment of metastatic pancreatic cancer.
“Receiving Fast Track designation is a significant milestone in our fight against pancreatic cancer,” said Sanjeev Luther, President and CEO of Rafael, in a press release. “This designation further stresses the severe unmet need in treatment options for this aggressive and devastating disease. We are truly thankful to the doctors, researchers, the FDA and all of our supporters who have made this possible. And most of all, we are grateful to the patients involved in our trials; the patients are the inspiration and driving force behind all of our efforts.”
Read the full press release here.